Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on June 10, 2016, regarding an event that occurred on June 9, 2016. The filing addresses corporate governance amendments to the company's By-Laws.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is non-financial in nature and contains no financial statements or performance data.
Material Changes
- By-Law Amendment: The Board of Directors amended the Restated and Amended By-Laws to reduce the quorum requirement for stockholder meetings.
- Quorum Reduction: The quorum was lowered from holders of a majority (50% + 1) of outstanding voting shares to holders of 40% of outstanding voting shares.
- Legal Driver: This change was mandated by a stipulation and agreement of settlement in the lawsuit Kastis v. Carter, et al. (No. 8657, Del. Ch.).
Guidance, Outlook, and Risks
The filing contains no management commentary on future guidance, outlook, or general business risks. The primary contingency noted is the ongoing legal settlement requiring the governance change. No unusual items or financial contingencies are disclosed in this document.
Key Facts for Investor Verification
- Verify the exact terms of the settlement agreement in Kastis v. Carter to understand the full scope of governance changes required.
- Review the attached Exhibit 3.1 (Amended and Restated By-Laws) for the complete legal text of the quorum reduction.
- Confirm that the company name in the metadata (AIM Immunotech Inc.) is incorrect; the registrant is Hemispherx Biopharma, Inc.